dalfopristin

dalfopristin

 [dal-fo´pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with quinupristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; administered intravenously.

dalfopristin

/dal·fo·pris·tin/ (dal-fo´pris-tin) a semisynthetic antibacterial used in conjunction with quinupristin against various gram-positive organisms, including vancomycin-resistant Enterococcus faecium.

dalfopristin

[dalfo′pristin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with quinupristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; it is administered intravenously.

dalfopristin

See Synercid®.
References in periodicals archive ?
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin.
Vancomycin, linezolid, gentamicin, moxifloxacin, quinupristin/ dalfopristin, and rifampicin were 100% effective (susceptible).
Based on the Naranjo probability scale, the likelihood that quinupristin dalfopristin caused the anemia and reticulocytopenia is probable.
5 mg/kg BID Vancomycin- dalfopristin resistant enterococci Linezolid 7.
aureus, which were resistant to three or more of the following agents: ciprofloxacin, clindamycin, erythromycin, gentamicin, oxacillin, quinupristin- dalfopristin, trimethoprim-sulfa, vancomycin, daptomycin, and linezolid.
Available options include vancomycin, linezolid, daptomycin, and quinupristin/ dalfopristin.
Although, as a streptogramin B, quinupristin is cross-resistant with macrolides and lincosamides, dalfopristin is a streptogramin A and not part of this resistance pattern.
It is a novel, injectable antibiotic made of two molecules: quinupristin and dalfopristin.
Resistance to erythromycin, clindamycin, tetracycline, and virginiamycin [an analog to quinupristin/ dalfopristin, which is used to treat vancomycin-resistant Enterococcus faecium infections in humans (Johnson and Livermore 1999)] was investigated.
The product is provided as a 30:70 ratio of quinupristin (pristinamycin I A, a group B streptogramin) and dalfopristin (pristinamycin II A, a group A streptogramin) (1, 2).
Although all of these linezolid-resistant isolates were still sensitive to the drug combination of quinupristin and dalfopristin (Synercid), the relatively high prevalence of linezolid resistance is "a cause for concern," said Paul C.
We tested the following: penicillin, amoxicillin, piperacillin, piperacillin and tazobactam, cefotaxime, ceftazidime, ertapenem, imipenem, meropenem, doripenem, gentamicin, tobramycin, amikacin, levofloxacin, ciprofloxacin, moxifloxacin, minocycline, tygecycline, cotrimoxazole, fosfomycin, quinupristin and dalfopristin, rifampin, daptomycin, linezolid, clindamycin, and fucidic acid.